Key facts
- This page summarizes Vanessa Malier's Form 4 filing for IO Biotech, Inc. (IOBT).
- 6 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 12 Nov 2021, 15:16.
Vanessa Malier - 09 Nov 2021 Form 4 Insider Report for IO Biotech, Inc. (IOBT)
- Reporting relationship
- Director
- Issuer ticker
- IOBT
- Reported as of
- 09 Nov 2021
- Net transaction value
- +$4,550,000
- SEC form
- 4
- Accepted by SEC
- 12 Nov 2021, 15:16:21 UTC
- Prior SEC filing
- 04 Nov 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian Burkavage, Attorney-in-Fact for Vanessa Malier
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Vanessa Malier filed Form 4 for IO Biotech, Inc. (IOBT) on 12 Nov 2021.
Change
- Previous filing in this sequence was filed on 04 Nov 2021.
- Current net transaction value: +$4,550,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IOBT
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +796,059
- Change %
- Price
- Shares after
- 796,059
- Date
- 09 Nov 2021
- Ownership
- See footnote
- Footnotes
- F1, F2
IOBT
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +267,977
- Change %
- Price
- Shares after
- 267,977
- Date
- 09 Nov 2021
- Ownership
- See footnote
- Footnotes
- F1, F3
IOBT
transaction
Common Stock
Purchase
- Transaction value
- $2,275,000
- Shares
- +162,500
- Change %
- +20%
- Price
- $14.00*
- Shares after
- 958,559
- Date
- 09 Nov 2021
- Ownership
- See footnote
- Footnotes
- F2
IOBT
transaction
Common Stock
Purchase
- Transaction value
- $2,275,000
- Shares
- +162,500
- Change %
- +61%
- Price
- $14.00*
- Shares after
- 430,477
- Date
- 09 Nov 2021
- Ownership
- See footnote
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IOBT
transaction
Derivative
Series C Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -63,350
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 09 Nov 2021
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 796,059
- Exercise price
- Footnotes
- F1, F2
IOBT
transaction
Derivative
Series C Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -21,325
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 09 Nov 2021
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 267,977
- Exercise price
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date.
Footnote F2
The securities are held by Kurma Biofund III FPCI. Kurma Partners is the management company of Kurma Biofund III FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by Kurma Biofund III FPCI and disclaims Section 16 beneficial ownership of such securities held by Kurma Biofund III FPCI, except to the extent of her pecuniary interest therein, if any.
Footnote F3
The securities are held by SKCI FPCI. Kurma Partners is the management company of SKCI FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by SKCI FPCI and disclaims Section 16 beneficial ownership of such securities held by SKCI FPCI, except to the extent of her pecuniary interest therein, if any.